Aquestive Therapeutics, Inc. (AQST) Stock Overview
Explore Aquestive Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Aquestive Therapeutics, Inc. (AQST)
Key Financials
Key Financials
Market Cap
584.7M
P/E Ratio
-7.19
EPS (TTM)
$-0.61
ROE
2.44%
AQST Stock Analysis & Investment Overview (NASDAQ)
Our AI-powered analysis of Aquestive Therapeutics, Inc. (NASDAQ: AQST) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Aquestive Therapeutics, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of AQST on the NASDAQ shows an RSI of 68.36, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $5.82 for the NASDAQ listing.
Key metrics behind Aquestive Therapeutics, Inc.'s NASDAQ-traded stock include a P/E ratio of -7.19 and a market capitalization of 584.7M. Combined with our AI analysis, these give both institutional and retail investors a clear view of AQST on the NASDAQ.